CNBC's Jim Cramer said Monday recent price adjustments from EpiPen's owner Mylan can be partially attributed to the rise of vocal social media platforms such as Twitter.
"When you raise prices for drugs that are for children, it gets social media," Cramer said on "Squawk on the Street." "One of the things that have changed is Twitter. The notion of building a regime of people who are angry."
Mylan announced Monday it would launch the first generic version of its life-saving EpiPen at a 50 percent discount to the branded's list price. The pharmaceutical company last week decreased the out-of-pocket costs of the auto-injector for some patients, but kept the list price at about $600.
Mylan's stock was trading slightly lower at $42.81 a share Monday morning.
Cramer added that diseases without a significant forum have a much harder time finding changes.
"It's more difficult when you have certain disease that don't have vocal ... lets say they don't have vocal moms," he said.